Prednisolone Acetate for Nasal Use: Dosage Recommendations
Prednisolone acetate is NOT approved for intranasal use by the FDA—it is an ophthalmic (eye) medication only. However, it has been used off-label for refractory nasal polyposis at a dose of 2 sprays per nostril twice daily using 1% prednisolone acetate ophthalmic suspension delivered via a standardized 15-mL nasal spray bottle 1, 2.
Critical Context: Off-Label Use
The FDA-approved indication for prednisolone acetate is exclusively for ophthalmic (eye) inflammation, not nasal conditions 1. The drug labeling provides no guidance on nasal dosing because this route is not approved 1.
Evidence-Based Off-Label Nasal Dosing
When prednisolone acetate has been studied for intranasal use in refractory nasal polyposis:
- Dose: 1% prednisolone acetate ophthalmic suspension
- Frequency: 2 sprays per nostril twice daily
- Delivery: Via 15-mL standardized nasal spray bottle
- Duration: 6-8 weeks studied
- Safety profile: No suppression of morning serum cortisol or ACTH levels at this dose 2
Why This Matters Clinically
For standard nasal polyposis treatment, use approved oral prednisolone instead, not the acetate ophthalmic formulation. The European Position Paper on Rhinosinusitis provides clear dosing for oral prednisolone in chronic rhinosinusitis with nasal polyps 3:
Recommended Oral Prednisolone Regimens:
- 25-50 mg daily for 14 days (most common evidence-based approach) 3
- Alternative: 60 mg for 7 days, then taper to 10 mg every other day through day 17 3
- Alternative: 30 mg daily for 7 days postoperatively 3
- Alternative: Methylprednisolone taper (32 mg days 1-5,16 mg days 6-10,8 mg days 11-20) 3
Clinical Outcomes with Oral Prednisolone:
These oral regimens produce significant improvements in:
- Nasal symptoms (obstruction, rhinorrhea, smell) at 2-12 weeks
- Nasal polyp scores
- Quality of life measures
- Peak nasal inspiratory flow 3
Important Caveats
Prednisolone acetate nasal spray is off-label: Only consider this in refractory cases after failure of standard therapies (intranasal corticosteroids, oral corticosteroid courses) 2
Standard first-line therapy: Use FDA-approved intranasal corticosteroids (mometasone, fluticasone, budesonide) at labeled doses 4
Short oral courses are preferred: When systemic steroids are needed, 1-2 courses per year of oral prednisolone can be added to nasal corticosteroids for partially controlled disease 3
Avoid confusion: Do not confuse prednisolone acetate (ophthalmic suspension) with oral prednisolone tablets—they are different formulations for different routes 1
Safety monitoring: If using off-label intranasal prednisolone acetate, the adrenal axis appears safe at the studied dose, but this remains an unapproved use 2
Bottom line: Use oral prednisolone 25-50 mg daily for 14 days for nasal polyps, not prednisolone acetate nasal spray, unless dealing with truly refractory disease where off-label use might be considered at 2 sprays per nostril twice daily.